Literature DB >> 19399753

Optimal clinical trial design using value of information methods with imperfect implementation.

Andrew R Willan1, Simon Eckermann.   

Abstract

Traditional sample size calculations for randomized clinical trials are based on the tests of hypotheses and depend on somewhat arbitrarily chosen factors, such as type I and II errors rates and the smallest clinically important difference. In response to this, many authors have proposed the use of methods based on the value of information as an alternative. Previous attempts have assumed perfect implementation, i.e. if current evidence favors the new intervention and no new information is sought or expected, all future patients will receive it. A framework is proposed to allow for this assumption to be relaxed. The profound effect that this can have on the optimal sample size and expected net gain is illustrated on two recent examples. In addition, a model for assessing the value of implementation strategies is proposed and illustrated.

Entities:  

Mesh:

Year:  2010        PMID: 19399753     DOI: 10.1002/hec.1493

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  29 in total

Review 1.  Sample size determination for cost-effectiveness trials.

Authors:  Andrew R Willan
Journal:  Pharmacoeconomics       Date:  2011-11       Impact factor: 4.981

2.  The value of value of information: best informing research design and prioritization using current methods.

Authors:  Simon Eckermann; Jon Karnon; Andrew R Willan
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

3.  Modeling the cost-effectiveness of strategies for treating esophageal adenocarcinoma and high-grade dysplasia.

Authors:  Louisa G Gordon; Nicholas G Hirst; George C Mayne; David I Watson; Timothy Bright; Wang Cai; Andrew P Barbour; Bernard M Smithers; David C Whiteman; Simon Eckermann
Journal:  J Gastrointest Surg       Date:  2012-05-30       Impact factor: 3.452

4.  Value of information and pricing new healthcare interventions.

Authors:  Andrew R Willan; Simon Eckermann
Journal:  Pharmacoeconomics       Date:  2012-06-01       Impact factor: 4.981

5.  Presenting evidence and summary measures to best inform societal decisions when comparing multiple strategies.

Authors:  Simon Eckermann; Andrew R Willan
Journal:  Pharmacoeconomics       Date:  2011-07       Impact factor: 4.981

6.  The Curve of Optimal Sample Size (COSS): A Graphical Representation of the Optimal Sample Size from a Value of Information Analysis.

Authors:  Eric Jutkowitz; Fernando Alarid-Escudero; Karen M Kuntz; Hawre Jalal
Journal:  Pharmacoeconomics       Date:  2019-07       Impact factor: 4.981

Review 7.  A systematic and critical review of the evolving methods and applications of value of information in academia and practice.

Authors:  Lotte Steuten; Gijs van de Wetering; Karin Groothuis-Oudshoorn; Valesca Retèl
Journal:  Pharmacoeconomics       Date:  2013-01       Impact factor: 4.981

Review 8.  Optimal global value of information trials: better aligning manufacturer and decision maker interests and enabling feasible risk sharing.

Authors:  Simon Eckermann; Andrew R Willan
Journal:  Pharmacoeconomics       Date:  2013-05       Impact factor: 4.981

9.  Can the real opportunity cost stand up: displaced services, the straw man outside the room.

Authors:  Simon Eckermann; Brita Pekarsky
Journal:  Pharmacoeconomics       Date:  2014-04       Impact factor: 4.981

Review 10.  Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes.

Authors:  Scott D Ramsey; William E Barlow; Ana M Gonzalez-Angulo; Sean Tunis; Laurence Baker; John Crowley; Patricia Deverka; David Veenstra; Gabriel N Hortobagyi
Journal:  Contemp Clin Trials       Date:  2012-09-18       Impact factor: 2.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.